Jump to content

Umeclidinium bromide/vilanterol

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 16:25, 3 May 2023 (Add: date. | Use this bot. Report bugs. | Suggested by Whywhenwhohow | #UCB_webform 545/569). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Umeclidinium bromide/vilanterol
Umeclidinium bromide (TOP), vilanterol (BOTTOM)
Combination of
Umeclidinium bromideMuscarinic antagonist
VilanterolUltra-long-acting β2 agonist
Clinical data
Trade namesAnoro Ellipta, Laventair Ellipta
AHFS/Drugs.comProfessional Drug Facts
License data
Pregnancy
category
  • AU: B3
Routes of
administration		Inhalation
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Umeclidinium bromide/vilanterol, sold under the brand name Anoro Ellipta, among others, is a fixed-dose combination medication for the treatment of chronic obstructive pulmonary disease (COPD).[4][5] It is administered by inhalation.

The most common side effects include upper respiratory tract infections (nose and throat infection), urinary tract infections (infection of the structures that carry urine), pharyngitis (inflammation of the throat), sinusitis (inflammation of the sinuses), nasopharyngitis (inflammation of the nose and throat), headache, cough, oropharyngeal pain (pain in the mouth and throat), constipation and dry mouth.[3]

In 2020, it was the 254th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[6][7]

References

  1. ^ "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
  2. ^ "Anoro Ellipta 55 micrograms/22 micrograms inhalation powder, pre-dispensed - Summary of Product Characteristics (SmPC)". (emc). 7 October 2019. Retrieved 29 October 2020.
  3. ^ a b "Anoro Ellipta EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 28 October 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  4. ^ Feldman GJ, Edin A (December 2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects". Therapeutic Advances in Respiratory Disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659. S2CID 5744282.
  5. ^ "FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. December 18, 2013.
  6. ^ "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
  7. ^ "Umeclidinium; Vilanterol - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.


Stub icon

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Umeclidinium_bromide/vilanterol&oldid=1153002428"